Sirtex Medical Ltd (SXMDF) 20.2500 $SXMDF
Sirtex Medical Inc. Announces 33 Percent Dose Sales Growth of SIR-Spheres(R) microspheres in Fourth Quarter
Business Wire - Mon Jul 07, 9:00AM CDT
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced dose sales of SIR-Spheres(R) microspheres grew 33 percent on a unit basis in the Americas region for the quarter ending June 30, 2014, compared to the previous corresponding period.
Brachytherapy Global Strategic Business Report 2014: Competition Heats Up in the Brachytherapy Market
M2 - Thu Jun 12, 5:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zllh3/brachytherapy) has announced the addition of the "Brachytherapy - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Brachytherapy in US$ Thousands. The report provides separate comprehensive analytics for the US, Canada, Japan Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 36 companies including many key and niche players such as: - Best Medical International - Best Vascular - Boston Scientific - COOK Medical - C. R. Bard - Eckert & Ziegler Strahlen & Medizintechnik - Gammex - Nucletron - Oncura - Sirtex Medical - Theragenics - Varian Medical Systems - Xoft Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW - Brachytherapy - A Prelude - The US Leads the Brachytherapy Devices Market Developing Regions to Spearhead Growth - Brachytherapy Provides More Hope for Cancer Patients Compared to EBRT - Comparison of Brachytherapy Over EBRT in Prostate Cancer Treatment - Growing Cancer Cases in Developing Countries Bodes Well for the Brachytherapy Market - Recent Technological Advancements Show Promising Future for the Brachytherapy Market 2. MAJOR MARKET DRIVERS, TRENDS & ISSUES 3. RESEARCH & STUDY FINDINGS 4. PROSTATE CANCER A MAJOR BRACHYTHERAPY INDICATION 5. OTHER MAJOR BRACHYTHERAPY INDICATIONS 6. PRODUCT OVERVIEW 7. BRACHYTHERAPY EQUIPMENT 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET IV. COMPETITIVE LANDSCAPE For more information visit http://www.researchandmarkets.com/research/7z...chytherapy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Sirtex and Guerbet to Collaborate on Clinical Studies in Primary and Secondary Liver Cancer
CNW Group - Mon Mar 24, 10:42AM CDT
Sirtex Medical Limited (ASX:SRX) and Guerbet S.A. (EPA:GBT) announce today that the two companies will enter into a major clinical studies collaboration in primary and secondary (metastatic) liver cancer. The objective of the collaboration is to examine how Sirtex's SIR-Spheres(®) microspheres and Guerbet's Lipiodol(®) may be combined or sequenced optimally - and further developed - to address the significant unmet clinical need in patients with hepatocellular carcinoma, metastatic colorectal cancer, metastatic neuroendocrine tumours, and a range of other primary and secondary liver cancers.
Sirtex and Guerbet Announce Collaboration On Clinical Studies in Liver Cancer
PR Newswire - Mon Mar 24, 10:25AM CDT
Sirtex Medical Limited (ASX: SRX) and Guerbet S.A. (GBT.PA) are pleased to announce today that the two companies are entering into a collaboration to advance research in primary and secondary metastatic liver cancer. The objective of the collaboration is to evaluate the unmet clinical need in patients with hepatocellular carcinoma, metastatic colorectal cancer, neuroendocrine tumors, and a range of other secondary liver cancers*.
Sirtex Medical Inc. Reports 23.7 Percent Dose Sales Growth of SIR-Spheres(R) microspheres in Second Quarter
Business Wire - Mon Jan 13, 9:00AM CST
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, recently announced that second quarter dose sales of SIR-Spheres(R) microspheres grew 23.7 percent in the Americas region compared to the previous corresponding period for the quarter ending December 31, 2013.
Sirtex Medical Inc. Reports 21 Percent Dose Sales Growth of SIR-Spheres(R) microspheres
Business Wire - Tue Sep 03, 10:44AM CDT
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, recently announced dose sales of SIR-Spheres microspheres grew a solid 21 percent with more than 4,750 doses being supplied in the Americas region for the year ending June 30, 2013.
Sirtex Reports 13.1 per cent Dose Sales Growth in Fourth Quarter
Business Wire - Wed Jul 03, 3:42AM CDT
Sirtex Medical Limited (ASX:SRX) today announced dose sales of its SIR-Spheres(R) microspheres targeted radiation therapy for liver cancer grew 13.1 per cent for the quarter ended 30 June 2013 compared to the previous corresponding period. For Financial Year 2013 dose sales of SIR-Spheres microspheres grew 19 per cent. Despite being off a higher base, the FY2013 result delivers continued strong dose sales growth following the 23 per cent growth in FY2012, 19 per cent growth in FY2011 and 14 per cent growth in FY2010.
Sirtex To Distribute Surefire Medical's Innovative Infusion System in Australia and Asia Pacific Markets
PR Newswire - Thu Jun 20, 5:00AM CDT
Sirtex Medical Limited (ASX: SRX) and US-based Surefire Medical today announced a sales and marketing partnership to distribute Surefire's range of innovative infusion systems and specialty catheters for the interventional radiology and oncology markets.
CEO of Sirtex Medical Gilman Wong Selected for Inclusion in The CEO Magazine
PRWeb - Mon May 27, 6:11AM CDT
On a beautiful night in Sydney, the publication that you hold in your hands hosted the 2012 Executive of the Year Awards, recognising Australia's best C-suite leaders. The top accolade for the evening went to Gilman Wong, CEO of Sirtex Medical. Gilman received the award for his tireless work with the global workforce that has brought hope and relief to people with inoperable liver cancer.
Sirtex Completes Patient Recruitment for SIRFLOX Study Evaluating SIR-Spheres(R) Microspheres as First-Line Treatment for Colorectal Liver Metastases
Business Wire - Sat Apr 13, 7:00AM CDT
Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced yesterday the completion of patient recruitment into the group's landmark SIRFLOX randomized controlled trial of SIR-Spheres(R) microspheres for patients with metastatic colorectal cancer. The SIRFLOX study is the world's largest randomized controlled trial in interventional oncology with more than 500 patients enrolled.
Sirtex Medical Inc. Announces Half-Year Dose Sales Report
Business Wire - Mon Mar 04, 8:50AM CST
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today that dose sales of SIR-Spheres(R) microspheres in the U.S. grew more than 35 percent for the first half of the company's fiscal year, compared to the same period last year. Globally the company reported dose sales growth of 30.5 percent in the six months ending Dec. 31, 2012.
Sirtex Medical Inc. Hosts Dinner Symposium at the 2013 American Hepato-Pancreato-Biliary Association's Annual Meeting
Business Wire - Tue Feb 19, 8:00AM CST
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today it will host a dinner symposium during the 2013 American Hepato-Pancreato-Biliary Association's (AHPBA) Annual Meeting. The educational event will take place Thursday, Feb. 21 from 7-8:30 p.m.at the Eden Roc Renaissance in Miami.
Sirtex Medical: Interim report - half-year ended 31 December 2012
Business Wire - Thu Feb 14, 7:00AM CST
--Global dose sales growth of 30.5 per cent
Sirtex Medical Inc. Announces Second Quarter Sales Growth
Business Wire - Tue Jan 15, 8:00AM CST
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today that dose sales of SIR-Spheres(R) microspheres in the U.S. grew 29 percent for the second quarter of fiscal year 2013 over the same period last year. Globally the company reported dose sales grew 25 percent year-on-year for the second fiscal quarter of 2013 ending Dec. 31, 2012.
Sirtex Medical Inc. Announces 33 Percent Dose Sales Growth of SIR-Spheres(R) microspheres in Fourth Quarter
Business Wire - Mon Jul 07, 9:00AM CDT
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced dose sales of SIR-Spheres(R) microspheres grew 33 percent on a unit basis in the Americas region for the quarter ending June 30, 2014, compared to the previous corresponding period.
Brachytherapy Global Strategic Business Report 2014: Competition Heats Up in the Brachytherapy Market
M2 - Thu Jun 12, 5:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zllh3/brachytherapy) has announced the addition of the "Brachytherapy - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Brachytherapy in US$ Thousands. The report provides separate comprehensive analytics for the US, Canada, Japan Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 36 companies including many key and niche players such as: - Best Medical International - Best Vascular - Boston Scientific - COOK Medical - C. R. Bard - Eckert & Ziegler Strahlen & Medizintechnik - Gammex - Nucletron - Oncura - Sirtex Medical - Theragenics - Varian Medical Systems - Xoft Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW - Brachytherapy - A Prelude - The US Leads the Brachytherapy Devices Market Developing Regions to Spearhead Growth - Brachytherapy Provides More Hope for Cancer Patients Compared to EBRT - Comparison of Brachytherapy Over EBRT in Prostate Cancer Treatment - Growing Cancer Cases in Developing Countries Bodes Well for the Brachytherapy Market - Recent Technological Advancements Show Promising Future for the Brachytherapy Market 2. MAJOR MARKET DRIVERS, TRENDS & ISSUES 3. RESEARCH & STUDY FINDINGS 4. PROSTATE CANCER A MAJOR BRACHYTHERAPY INDICATION 5. OTHER MAJOR BRACHYTHERAPY INDICATIONS 6. PRODUCT OVERVIEW 7. BRACHYTHERAPY EQUIPMENT 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET IV. COMPETITIVE LANDSCAPE For more information visit http://www.researchandmarkets.com/research/7z...chytherapy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Sirtex and Guerbet to Collaborate on Clinical Studies in Primary and Secondary Liver Cancer
CNW Group - Mon Mar 24, 10:42AM CDT
Sirtex Medical Limited (ASX:SRX) and Guerbet S.A. (EPA:GBT) announce today that the two companies will enter into a major clinical studies collaboration in primary and secondary (metastatic) liver cancer. The objective of the collaboration is to examine how Sirtex's SIR-Spheres(®) microspheres and Guerbet's Lipiodol(®) may be combined or sequenced optimally - and further developed - to address the significant unmet clinical need in patients with hepatocellular carcinoma, metastatic colorectal cancer, metastatic neuroendocrine tumours, and a range of other primary and secondary liver cancers.
Sirtex and Guerbet Announce Collaboration On Clinical Studies in Liver Cancer
PR Newswire - Mon Mar 24, 10:25AM CDT
Sirtex Medical Limited (ASX: SRX) and Guerbet S.A. (GBT.PA) are pleased to announce today that the two companies are entering into a collaboration to advance research in primary and secondary metastatic liver cancer. The objective of the collaboration is to evaluate the unmet clinical need in patients with hepatocellular carcinoma, metastatic colorectal cancer, neuroendocrine tumors, and a range of other secondary liver cancers*.
Sirtex Medical Inc. Reports 23.7 Percent Dose Sales Growth of SIR-Spheres(R) microspheres in Second Quarter
Business Wire - Mon Jan 13, 9:00AM CST
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, recently announced that second quarter dose sales of SIR-Spheres(R) microspheres grew 23.7 percent in the Americas region compared to the previous corresponding period for the quarter ending December 31, 2013.
Sirtex Medical Inc. Reports 21 Percent Dose Sales Growth of SIR-Spheres(R) microspheres
Business Wire - Tue Sep 03, 10:44AM CDT
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, recently announced dose sales of SIR-Spheres microspheres grew a solid 21 percent with more than 4,750 doses being supplied in the Americas region for the year ending June 30, 2013.
Sirtex Reports 13.1 per cent Dose Sales Growth in Fourth Quarter
Business Wire - Wed Jul 03, 3:42AM CDT
Sirtex Medical Limited (ASX:SRX) today announced dose sales of its SIR-Spheres(R) microspheres targeted radiation therapy for liver cancer grew 13.1 per cent for the quarter ended 30 June 2013 compared to the previous corresponding period. For Financial Year 2013 dose sales of SIR-Spheres microspheres grew 19 per cent. Despite being off a higher base, the FY2013 result delivers continued strong dose sales growth following the 23 per cent growth in FY2012, 19 per cent growth in FY2011 and 14 per cent growth in FY2010.
Sirtex To Distribute Surefire Medical's Innovative Infusion System in Australia and Asia Pacific Markets
PR Newswire - Thu Jun 20, 5:00AM CDT
Sirtex Medical Limited (ASX: SRX) and US-based Surefire Medical today announced a sales and marketing partnership to distribute Surefire's range of innovative infusion systems and specialty catheters for the interventional radiology and oncology markets.
CEO of Sirtex Medical Gilman Wong Selected for Inclusion in The CEO Magazine
PRWeb - Mon May 27, 6:11AM CDT
On a beautiful night in Sydney, the publication that you hold in your hands hosted the 2012 Executive of the Year Awards, recognising Australia's best C-suite leaders. The top accolade for the evening went to Gilman Wong, CEO of Sirtex Medical. Gilman received the award for his tireless work with the global workforce that has brought hope and relief to people with inoperable liver cancer.
Sirtex Completes Patient Recruitment for SIRFLOX Study Evaluating SIR-Spheres(R) Microspheres as First-Line Treatment for Colorectal Liver Metastases
Business Wire - Sat Apr 13, 7:00AM CDT
Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced yesterday the completion of patient recruitment into the group's landmark SIRFLOX randomized controlled trial of SIR-Spheres(R) microspheres for patients with metastatic colorectal cancer. The SIRFLOX study is the world's largest randomized controlled trial in interventional oncology with more than 500 patients enrolled.
Sirtex Medical Inc. Announces Half-Year Dose Sales Report
Business Wire - Mon Mar 04, 8:50AM CST
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today that dose sales of SIR-Spheres(R) microspheres in the U.S. grew more than 35 percent for the first half of the company's fiscal year, compared to the same period last year. Globally the company reported dose sales growth of 30.5 percent in the six months ending Dec. 31, 2012.
Sirtex Medical Inc. Hosts Dinner Symposium at the 2013 American Hepato-Pancreato-Biliary Association's Annual Meeting
Business Wire - Tue Feb 19, 8:00AM CST
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today it will host a dinner symposium during the 2013 American Hepato-Pancreato-Biliary Association's (AHPBA) Annual Meeting. The educational event will take place Thursday, Feb. 21 from 7-8:30 p.m.at the Eden Roc Renaissance in Miami.
Sirtex Medical: Interim report - half-year ended 31 December 2012
Business Wire - Thu Feb 14, 7:00AM CST
--Global dose sales growth of 30.5 per cent
Sirtex Medical Inc. Announces Second Quarter Sales Growth
Business Wire - Tue Jan 15, 8:00AM CST
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today that dose sales of SIR-Spheres(R) microspheres in the U.S. grew 29 percent for the second quarter of fiscal year 2013 over the same period last year. Globally the company reported dose sales grew 25 percent year-on-year for the second fiscal quarter of 2013 ending Dec. 31, 2012.
